Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Non-Current Assets (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Non-Current Assets data on record, last reported at $1.5 billion in Q1 2026.

  • On a quarterly basis, Non-Current Assets fell 7.63% to $1.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.5 billion, a 7.63% decrease, with the full-year FY2025 number at $1.4 billion, down 20.19% from a year prior.
  • Non-Current Assets reached $1.5 billion in Q1 2026 per PCVX's latest filing, up from $1.4 billion in the prior quarter.
  • Over the last five years, Non-Current Assets for PCVX hit a ceiling of $1.7 billion in Q4 2024 and a floor of $42.3 million in Q3 2022.
  • A 5-year average of $758.9 million and a median of $574.2 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: skyrocketed 570.85% in 2024, then fell 20.19% in 2025.
  • Tracing PCVX's Non-Current Assets over 5 years: stood at $63.6 million in 2022, then soared by 390.33% to $312.0 million in 2023, then skyrocketed by 452.42% to $1.7 billion in 2024, then dropped by 20.19% to $1.4 billion in 2025, then increased by 11.59% to $1.5 billion in 2026.
  • Business Quant data shows Non-Current Assets for PCVX at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.